Palisade Bio, INC Schedule 13G passive stakes

Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz have jointly filed a Schedule 13G, reporting no beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026.

Soleus Capital Master Fund, L.P. and affiliated entities have disclosed beneficial ownership of 7.5% of Palisade Bio, Inc.'s common stock.

Soleus Capital Master Fund and affiliated entities have reported a 5.4% beneficial ownership stake in Palisade Bio, Inc. common stock.

RA Capital Management and its principals report a 9.9% beneficial ownership stake in Palisade Bio, Inc. as of March 31, 2026.

Point72 Asset Management, L.P. and Steven A. Cohen have filed a Schedule 13G reporting a 0.2% beneficial ownership stake in Palisade Bio, Inc.

Commodore Capital LP and its principals have reported a 7.2% beneficial ownership stake in Palisade Bio, Inc. through a combination of common stock and pre-funded warrants.

Perceptive Advisors LLC and Joseph Edelman have reported a 7.9% beneficial ownership stake in Palisade Bio, Inc. through the Perceptive Life Sciences Master Fund.

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have reported beneficial ownership of 5.3% of Palisade Bio, Inc.'s common stock as of March 31, 2026.

Squadron Master Fund LP, along with related entities and individuals, has disclosed a 3.0% passive beneficial ownership stake in Palisade Bio, Inc.

Deep Track Capital and its affiliated entities have reported a complete divestment of their beneficial ownership in Palisade Bio, Inc., holding 0% of the common stock.

Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP and Ting Jia, has reported a 6.4% beneficial ownership stake in Palisade Bio, Inc.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have reported a 6.0% beneficial ownership stake in Palisade Bio, Inc., including shares from warrant exercises.

Janus Henderson Group plc and its affiliates have reported a 9.99% beneficial ownership stake in Palisade Bio, Inc. common stock.

RA Capital Management and its affiliates have reported a 9.9% passive beneficial ownership stake in Palisade Bio, Inc. common stock.

Perceptive Advisors LLC and its affiliates have reported a 9.99% beneficial ownership stake in Palisade Bio, Inc., totaling 12,243,018 shares.

Squadron Master Fund LP and affiliated entities have reported beneficial ownership of up to 8.5% of Palisade Bio, Inc.'s common stock.

Commodore Capital LP and its affiliates have reported a 9.9% passive ownership stake in Palisade Bio, Inc., totaling 9,690,665 shares.

Deep Track Capital and its affiliates have reported a 9.99% beneficial ownership stake in Palisade Bio, Inc. common stock.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly reported a 6.2% beneficial ownership stake in Palisade Bio, Inc.

Armistice Capital and Steven Boyd report a 4.99% passive ownership stake in Palisade Bio, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a 9.99% beneficial ownership stake in Palisade Bio, Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Palisade Bio, Inc. as of December 31, 2024, through an amended Schedule 13G filing.